The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 1
- 主要终点
- Postoperative tumor recurrence rate
研究概览
简要总结
The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.
详细描述
This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 90 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •These patients were scheduled for elective liver resection to treat hepatocellular carcinoma or adenocarcinoma of the liver.
排除标准
- •a body-weight loss greater than 10% during the 6 months prior to surgery,
- •the presence of distant metastases, or
- •serious impairment of organ function due to respiratory, renal, or heart disease.
研究组 & 干预措施
LIVACT
The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
干预措施: LIVACT (Drug)
结局指标
主要结局
Postoperative tumor recurrence rate
时间窗: 5 years follow up
次要结局
- nutritional status(5 years follow up)
研究者
Takehiro Okabayashi
Kochi Medical School
Kochi University